Jastreboff 2022 — SURMOUNT-1 Tirzepatide Pivotal

New England Journal of Medicine·July 21, 2022

Ania M. Jastreboff, Louis J. Aronne, Nadia N. Ahmad, Sean Wharton, Lisa Connery, et al.

Summary

Landmark obesity trial. Mean weight reductions: 5mg -15%, 10mg -19.5%, 15mg -20.9% vs placebo -3.1% at 72 weeks. Set new standard for weight loss efficacy.

Study Details

Study Design

Phase 3 randomized, double-blind, placebo-controlled trial

Indication

Obesity or overweight

Intervention

Tirzepatide 5, 10, or 15 mg weekly vs placebo

Species

Human

Sample Size

2,539 subjects

Risk of Bias Assessment

Sponsor-funded